radioligand therapy for prostate cancerProjects

Projects

NIH-funded projects in the analyzed sample, ranked by relevance to the topic. Funding shown as scale context, not the sort key.

Top 20 by Relevance(20)

Showing 20 of 115

Project	PI	Organization	Category	Funding
PSMA ligand radiosensitizers to improve the therapeutic index of external beam radiotherapy for prostate cancer 5R03CA286680-02	HIGGINSON, DANIEL	SLOAN-KETTERING INST CAN RESEARCH	Therapeutics	$176K
Improving PSMA-based radioligand therapy via combination radioligand therapy ZIABC011895	LIN, FRANK (contact)	DIVISION OF BASIC SCIENCES - NCI	Therapeutics	$321K
MELT: Modulation of PSMA Expression for Lutetium Therapy 5R01CA235741-06	HOPE, THOMAS A.	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	Therapeutics	$1.1M
Targeting tumor microenvironment-mediated radiopharmaceutical therapy resistance in prostate cancer 1R21CA303173-01	ABT, EVAN ROBERT	UNIVERSITY OF CALIFORNIA LOS ANGELES	Medical Device	$405K
Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalization 5R01CA289631-02	DEWARAJA, YUNI K	UNIVERSITY OF MICHIGAN AT ANN ARBOR	Therapeutics	$644K
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation P01CA250972	MCNEEL, DOUGLAS G. (contact)	UNIVERSITY OF WISCONSIN-MADISON	Therapeutics	$2.4M
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors 5R01CA243014-06	MENDA, YUSUF	UNIVERSITY OF IOWA	Therapeutics	$167K
Systematic Testing of a TGFβ Targeted Theranostic in Preclinical Cancer 5R01CA297601-02	BARCELLOS-HOFF, MARY HELEN	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	Therapeutics	$1.3M
Deep Learning-Based Treatment Planning for PSMA RPT 5R01CA296305-02	EL FAKHRI, GEORGES	YALE UNIVERSITY	Therapeutics	$1.1M
Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate R01CA286918	BODEI, LISA (contact)	SLOAN-KETTERING INST CAN RESEARCH	Basic Research	$1.4M
Highly selective targeted theranostics for prostate cancers 5R01CA255925-04	BASILION, JAMES PETER	CASE WESTERN RESERVE UNIVERSITY	Therapeutics	$635K
Combining antigen-specific vaccination with radiopharmaceutical therapy (RPT) to enhance anti-tumor immunity and efficacy F31CA305954	SHIM, DAEUN	UNIVERSITY OF WISCONSIN-MADISON	Training	$76K
Enhancing Prostate Cancer Treatment Outcomes with Combined Radioimmunotherapy and Antibody Drug Conjugates K99CA304511	BIDKAR, ANIL PARSRAM	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	Training	$372K
PSMA-targeted AuNPs for MR guided radiotherapy and radiosensitization R01CA260847	AYDOGAN, BULENT	CASE WESTERN RESERVE UNIVERSITY	Therapeutics	$632K
Alpha-Particle Emitter Radiopharmaceutical Therapy for Liver Cancer R01CA239041	NEDROW, JESSIE (contact)	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	Therapeutics	$574K
The Radium-223 Combination Therapy Space; Improving Response and Clarifying Toxicities R01CA240711	MICHALSKI, JEFF M.	WASHINGTON UNIVERSITY	Therapeutics	$414K
Targeting androgen receptor nuclear localization in prostate cancer 5R01CA265897-04	WANG, ZHOU	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	Basic Research	$730K
Targeting androgen receptor with non-steroidal next-generation radiopharmaceuticals K99CA312787	JALLINOJA, VILMA I.	SLOAN-KETTERING INST CAN RESEARCH	Training	$153K
The Development of Radiolabeled PSMA Agent with Low Salivary Gland Uptake 1R41CA285188-01A1	WU, ZHANHONG	TRIPILL BIOTECHNOLOGY, CORP.	Biotools	$400K
Combination Radiopharmaceutical Therapy and External Beam Radiotherapy 5R01CA240779-06	HOBBS, ROBERT FRANCOIS	JOHNS HOPKINS UNIVERSITY	Therapeutics	$968K

$105.9M total funding across the analyzed sample